Natural Gas Services Group: Complete Genomics Expands Manufacturing for Enhanced Genomic Sequencing Solutions
- Complete Genomics expands U.S. manufacturing in 2024 to enhance its genomic sequencing supply chain and efficiency.
- The new San Jose facility will produce the swift DNBSEQ-G99RS sequencers, ensuring timely product delivery to customers.
- Collaborations with NVIDIA and Eurofins signal a focus on innovation and improved sequencing solutions in the biotech industry.
Complete Genomics Expands Manufacturing to Strengthen Genomic Sequencing Supply Chain
Complete Genomics, a prominent player in the genomic sequencing field, undertakes a major expansion of its U.S. manufacturing capabilities in 2024, reflecting a strategic move to enhance its supply chain and deliver next-generation sequencing (NGS) solutions more efficiently. The expansion comes in the wake of a challenging year that saw geopolitical tensions and the failure of the BIOSECURE Act, which sought to regulate genetic data security. By opening two new facilities, most notably a 10,115 square foot manufacturing plant in San Jose, California, Complete Genomics aims to provide local, reliable supply chain solutions for its North American customers.
The San Jose facility is pivotal for the production of the DNBSEQ-G99RS ("G99") sequencers, known for their swift 12-hour run time and the capacity for preliminary reporting in just 2.5 hours. This significant achievement not only streamlines operations but also ensures that customers receive their products in a timely manner. Furthermore, the company celebrates the attainment of its first Nationally Recognized Testing Laboratory (NRTL) certification for G99 production in North America, a critical milestone that underscores its commitment to quality and safety. In tandem with these efforts, Complete Genomics plans to enhance its reagent production capabilities for both the G99 and DNBSEQ-T7RS ("T7") platforms, with aspirations for ISO 13485 certification, thereby solidifying its position in the genomics market.
Looking ahead, Complete Genomics sets its sights on 2025 with plans to manufacture the T7 in the United States, a move that aligns with its localization strategy and further strengthens its North American presence. In addition, the company opens a Customer Experience Center (CEC) in Framingham, Massachusetts, designed to showcase DNBSEQ workflows and foster deeper engagement with customers. Throughout 2024, Complete Genomics also forges strategic partnerships with industry leaders such as NVIDIA and Eurofins Clinical Enterprise, allowing it to broaden its service offerings and enhance its market reach. These initiatives collectively demonstrate Complete Genomics' dedication to advancing genomic technology and improving customer experience in the biotech industry.
Related Cashu News

Kosmos Energy Gains Inclusion in Russell Indices Amidst Stock Volatility and Growth Potential
Kosmos Energy (Ticker: KOS) is experiencing a significant shift in its market presence as it gains inclusion in key Russell growth benchmark indices, notably the Russell 2000 Growth and Russell 3000 G…

Chevron Navigates Rising Gas Prices and Tax Increases Amid California's Energy Policy Debate
Chevron (Ticker: CVX) faces a complex landscape in California as high fuel prices continue to burden residents. Recent developments signal the impending gas tax increase slated to raise California's e…

ConocoPhillips Enhances Capital Flexibility Amidst Rising Fuel Prices and Market Volatility
ConocoPhillips (Ticker: COP) actively positions itself in the evolving energy sector by filing a new Shelf Registration, a strategic maneuver that enhances its ability to raise capital flexibly. This…

SLB Launches Digital Marketplace to Enhance Innovation and Market Position in Energy Sector
SLB (Ticker: SLB) announces the launch of the SLB Digital Marketplace, a significant development that bolsters its technological presence within the energy sector. This new platform features roughly 2…

